Secukinumab provides better relief from the impact of psoriasis on daily activities and personal relationships than etanercept: results of two phase 3 placebo-controlled randomized clinical trials in moderate-to-severe psoriasis.
BACKGROUND
Psoriasis can greatly impact patients' lives, influencing what clothing they wear and impairing their sexual functioning.


OBJECTIVE
To provide a detailed comparison of the impact of secukinumab vs. etanercept on enabling patients with psoriasis to have more normal lives with respect to daily activities (DA) (e.g. choosing clothing) and personal relationships (PR) (e.g. sexual functioning).


METHODS
Baseline to Week 52 ERASURE and FIXTURE data for secukinumab 300 mg and etanercept were analyzed. Treatment differences in mean scores on the DA and PR subscales and items from the Dermatology Life Quality Index were compared. The proportions of subscale and item responders (score = 0) were compared.


RESULTS
Subjects receiving secukinumab (n = 572) achieved greater mean improvement in DA and items (q3 and q4) than subjects receiving etanercept (n = 326; all p < .01 through Week 52). Subjects receiving secukinumab achieved greater mean improvement in PR and items (q8 and q9) than subjects receiving etanercept (subscale: p < .05 at Weeks 8 and 12). Response rates were significantly higher for secukinumab than for etanercept for DA (all p < .0001) and PR (all p < .05 except Weeks 4 and 36).


CONCLUSIONS
Secukinumab 300 mg provides greater improvements and more effective relief from psoriasis impact on DA and PR than etanercept.
a University Hospitals Cleveland Medical Center , Cleveland , OH , USA.
Neil J
NJ
Korman
b Department of Medicine/Dermatology , University of California at Los Angeles , Los Angeles , CA , USA.
Howard
H
Sofen
c Dawes Fretzin Dermatology Group , Indianapolis , IN , USA.
Scott
S
Fretzin
d Oregon Dermatology and Research Center , Portland , OR , USA.
Phoebe
P
Rich
e Novartis Pharmaceuticals Corporation , One Health Plaza , East Hanover , NJ , USA.
Yang
Y
Zhao
e Novartis Pharmaceuticals Corporation , One Health Plaza , East Hanover , NJ , USA.
Vivian
V
Herrera
e Novartis Pharmaceuticals Corporation , One Health Plaza , East Hanover , NJ , USA.
Judit
J
Nyirady
f RTI Health Solutions , Research Triangle Park , NC , USA.
Nicole
N
Williams
g RTI Health Solutions , Ann Arbor , MI , USA.
Margaret
M
Mordin
h Department of Dermatology , University of Texas Health Science Center , Houston , TX , USA.
Stephen
S
Tyring
D000203:Activities of Daily Living; D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D004311:Double-Blind Method; D000068800:Etanercept / Q000627:therapeutic use*; D005195:Family Relations; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D015990:Placebo Effect; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012720:Severity of Illness Index; D016896:Treatment Outcome
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D007166:Immunosuppressive Agents; C555450:secukinumab; D000068800:Etanercept
DLQI; Psoriasis; clothing choice; daily activities; health-related quality of life; personal relationships; secukinumab